Akademik Veri Yönetim Sistemi
EJONS 16th INTERNATIONAL CONFERENCE ON MATHEMATICS, ENGINEERING, NATURAL & MEDICAL SCIENCES, İstanbul, Türkiye, 11 - 13 Kasım 2023, ss.101-110, (Tam Metin Bildiri)
Multidrug resistance protein 1 (MRP1), which can protect cells from toxic insults, mediates the
transportation of the cysteinyl leukotriene C4 (LTC4) that has been correlated with the
pathophysiology of asthma. MRP1 activity in allergic asthma patients and the effect of MRP1
inhibition were investigated. 32 asthma patients [mild persistent (n=13) and mild intermittent
(n=19)] and healthy controls (n=22) were evaluated. MRP1 gene expressions were detected in
leukocytes by using quantitative PCR. MRP1 efflux function was assessed by incubating leukocytes with Calcein-AM and comparing calcein fluorescence with and without the
modulator probenecid. LTC4 release in vitro from cells was assessed by ELISA. Effects of
MRP1 inhibition was evaluated by flow cytometer after probenecid induction in the leucocytes.
LTC4 levels detected by ELISA and ATP levels by chemiluminescence technic. MRP1 gene
expression were found to be increased compared to the controls (p=0.003 by unpaired t-test).
Significantly low LTC4 levels were detected in the leucocytes supernatants of asthmatic
patients (p=0.004) and MRP1 regulated transport of LTC4 was found faster than control group.
ATP levels were also significantly reduced (p=0.03). In the mild persistent asthma group. In
addition, the activity of MRP1 transport proteins was found to be increased in asthma
(p=0.031). Based on our results, we can suggest that MRP1 plays a role in the compensation
mechanism in asthma pathogenesis by ensuring LT transport in allergic asthma. Inhibition of
MRP1 may attract the attention of clinicians by providing a new perspective on treatment
protocols aiming to prevent and reduce cell activation in asthma.